Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Citric acid, gluconolactone and magnesium carbonate

Drug class: Calculi Dissolution Agent, Anti-coagulant

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Citric acid, gluconolactone and magnesium carbonate key facts

Drug class
Calculi Dissolution Agent
Used for
Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (December 17, 2019); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Citric acid, gluconolactone and magnesium carbonate used for?
The FDA-approved label (Renacidin, United-Guardian, Inc., December 17, 2019) says: “Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Citric acid, gluconolactone and magnesium carbonate?
The “Adverse Reactions” section of the FDA label (Renacidin, United-Guardian, Inc., December 17, 2019) begins: “The most common adverse reactions with use of Renacidin for dissolution of bladder calculi or prevention of encrustations of indwelling urethral catheters are “bladder irritability” and chemical cystitis, both reported to occur in approximately 3% of patients. A transient burning sensation in the bladder following Renacidin has been reported to occur in less than 1% of patients receiving Renacidin.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Citric acid, gluconolactone and magnesium carbonate have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Citric acid, gluconolactone and magnesium carbonate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Citric acid, gluconolactone and magnesium carbonate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Citric acid, gluconolactone and magnesium carbonate?
1 company lists prescription products of Citric acid, gluconolactone and magnesium carbonate in the FDA NDC Directory, including United-Guardian, Inc.

What Citric acid, gluconolactone and magnesium carbonate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes.

— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →

Label quoted: the one for the most common form (solution, irrigation), Renacidin, United-Guardian, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Citric acid, gluconolactone and magnesium carbonate side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The most common adverse reactions with use of Renacidin for dissolution of bladder calculi or prevention of encrustations of indwelling urethral catheters are “bladder irritability” and chemical cystitis, both reported to occur in approximately 3% of patients. A transient burning sensation in the bladder following Renacidin has been reported to occur in less than 1% of patients receiving Renacidin.

— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →

Citric acid, gluconolactone and magnesium carbonate dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

Renacidin for local irrigation within the lower urinary tract is available in single-use 30 mL containers. Prepare and Administer the Dose: Step 1: Inspect Renacidin visually for particulate matter and discoloration prior to administration. If particulate matter or discoloration are observed, do not administer. Step 2: Remove the plastic tab connected to the conical tip of the Renacidin container by twisting the plastic tab. See Figure 1.

Read more of this section

Figure 1 Step 3: Connect the conical tip of the Renacidin container to the end of the urethral catheter or cystostomy tube. See Figure 2. Figure 2 Step 4: Squeeze the Renacidin container to expel the entire contents into the urethral catheter or cystostomy tube. See Figure 3. Figure 3 For Dissolution of Bladder Calculi: Instill 30 mL (one container) of Renacidin into the bladder via a urethral catheter or cystostomy tube. Clamp the urethral catheter or cystostomy tube for 30 to 60 minutes. Release the clamp and drain the bladder. Repeat the instillation procedure 4 to 6 times a day. Monitor for dissolution of calculi. For Prevention of Encrustations in Urethral Catheters and Cystostomy Tubes: Instill 30 mL (one container) of Renacidin into the urethral catheter or cystostomy tube. Clamp the urethral catheter or cystostomy tube for 10 minutes. Remove the clamp and drain the bladder. Repeat the instillation procedure 3 times a day. Figure 1 Figure 2 Figure 3

— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →

Citric acid, gluconolactone and magnesium carbonate in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Category C Animal reproduction studies have not been conducted with Renacidin. It is also not known whether Renacidin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Renacidin should be given to a pregnant woman only if clearly needed.

— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →

Citric acid, gluconolactone and magnesium carbonate and breastfeeding

Quoted from the nursing mothers / lactation part of the FDA-approved label.

Magnesium is known to be excreted into human milk. It is not known whether Renacidin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Renacidin is administered to a nursing woman.

— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →

When Citric acid, gluconolactone and magnesium carbonate should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Renacidin is contraindicated in the presence of demonstrable urinary tract extravasation.

— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →

Forms and how it is given

Dosage formsSolution
RouteIrrigation
Prescription products1 in the FDA NDC Directory
Brand namesRenacidin

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA019481
RENACIDIN
United GuardianOctober 2, 1990 10, latest December 16, 2015
2015: Manufacturing (CMC) · 2015: Labeling · 2014: Manufacturing (CMC)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)1792396, 1792398
SPL set ID of the quoted label13a9bbba-db21-4cba-991c-5d8afaf2ed74
FDA labels (SPL)1
FDA applicationsNDA019481
Active ingredients (FDA)ANHYDROUS CITRIC ACID / GLUCONOLACTONE / MAGNESIUM CARBONATE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Renacidin, United-Guardian, Inc., effective December 17, 2019; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers